

Tyrosine kinase inhibitors for cancer treatment

Citation for published version (APA):

Tullemans, B. M. E. (2021). *Tyrosine kinase inhibitors for cancer treatment: effects on platelets*. [Doctoral Thesis, Maastricht University]. ProefschriftMaken. <https://doi.org/10.26481/dis.20211006bt>

Document status and date:

Published: 01/01/2021

DOI:

[10.26481/dis.20211006bt](https://doi.org/10.26481/dis.20211006bt)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Stellingen behorende bij het proefschrift:

Tyrosine kinase inhibitors for cancer treatment: Effects on platelets

1. Meerdere tyrosine-kinaseremmers die klinisch worden gebruikt voor tumor-suppressie hebben een remmend effect op de functie van bloedplaatjes. *(Dit proefschrift)*
2. Plasma-eiwitten kunnen een modulerend effect hebben op de werkzaamheid van tyrosine-kinaseremmers met betrekking tot de remming van bloedplaatjesfunctie. *(Dit proefschrift)*
3. De concentratie van sunitinib in het bloed weerspiegelt het remmend effect op bloedplaatjes tijdens behandeling van de patiënt. *(Dit proefschrift)*
4. Toegelaten tyrosine-kinaseremmers zijn mogelijk geschikt voor antiplaatjes-behandeling. *(Dit proefschrift)*
5. De waargenomen rol van bloedplaatjes bij kankerprogressie en metastase suggereert dat comediatie met aspirine ook een anticarcinogeen effect heeft. *(Gresele, Cancer Metastasis Rev 2017)*
6. Off-label gebruik van Btk-remmers kan mogelijk een veilig alternatief zijn voor de behandeling van vaccinatie-geïnduceerde immuun-trombotische trombocytopenie na ChadOx1 nCoV-19-injectie. *(Von Hundelshausen, Thromb Haemost 2021)*
7. Testen van de bloedplaatjesactiviteit in zowel volbloed als na isolatie is nodig voor het goed begrijpen van farmacologische effecten op de complexe functies van bloedplaatjes.
8. Meer uitgebreid onderzoek naar de off-target effecten van antikankermedicijnen kan nieuwe handvaten bieden voor het verbeteren van de antitumorbehandeling en de kwaliteit van leven van de patiënt.
9. In het rijk van ideeën hangt alles af van enthousiasme, in de echte wereld hangt alles af van doorzettingsvermogen. *(Johann Wolfgang von Goethe)*
10. Als we wisten wat we aan het doen waren, zou het toch geen onderzoek heten? *(Albert Einstein)*
11. Nieuwsgieriger en nieuwsgieriger! *(Alice in Wonderland)*

Bibian Tullemans, 6 oktober 2021

Propositions belonging to this dissertation:

Tyrosine kinase inhibitors for cancer treatment: Effects on platelets

1. Several tyrosine kinase inhibitors used for tumour suppression have an inhibitory effect on platelet function. *(This thesis)*
2. Plasma proteins can have a modulating effect on the effectivity of tyrosine kinase inhibitors with respect to the inhibition on platelet function. *(This thesis)*
3. The concentration of sunitinib in the blood reflects the inhibitory effect on platelets in patients upon treatment. *(This thesis)*
4. Approved tyrosine kinase inhibitors might be promising candidates for antiplatelet therapy. *(This thesis)*
5. The observed role of platelets in cancer progression and metastasis suggests that co-therapies such as aspirin also have an anticarcinogenic effect. *(Gresele, Cancer Metastasis Rev 2017)*
6. Off-label use of Btk inhibitors could be considered a sufficiently safe option to treat Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChadOx1 nCov-19 injection. *(Von Hundelshausen, Thromb Haemost 2021)*
7. Testing platelet activity in both whole blood, as well as isolated conditions is necessary to understand the pharmacological effects on the complex mechanisms of platelet function.
8. More extensive research into the off-target effects of anticancer drugs might provide important information for improving cancer treatment and the patients' quality of life.
9. In the realm of ideas everything depends on enthusiasm, in the real world all rests on perseverance. *(Johann Wolfgang von Goethe)*
10. If we knew what it was we were doing, it would not be called research, would it? *(Albert Einstein)*
11. Curiouser and curiouser! *(Alice in Wonderland)*